Introduction to Pharmacology & Its General Principles Flashcards
medyo oa (180 cards)
1
Q
What century where reliance on observation and experimentation began to replace theorizing in physiology and clinical medicine
A
End of 17th Century
2
Q
Origin of ancient drugs
A
Plants
3
Q
Science of drug preparation and the medical uses of drugs and identifies receptors
A
Materia Medica
4
Q
The precursor to Pharmacology
A
Materia Medica
5
Q
T/F: Any real understanding of the mechanisms of action of drugs was prevented by the absence of methods for purifying active agents from the crude materials that were available
A
True
6
Q
Who developed the methods of experimental physiology and pharmacology; which has laid the foundation needed for understanding how drugs work at the organ and tissue levels.
A
Francois Magendie & Claude Bernard (Maganda & Cathryn Bernardo)
7
Q
Real advances in basic pharmacology during this time were accompanied by an outburst of unscientific claims that marketed worthless patent medicines
A
Late 18th & Early 19th Century
8
Q
Information accumulated about the drug action and biologic substrate of that action
A
Drug Receptor (1940s & 1950s)
9
Q
Receptors for which no ligand has been discovered and whose function can only be guessed.
A
Orphan Receptors
10
Q
Receptors and effectors do not function in isolation; they are strongly influenced by other receptors and by
A
Companion Regulatory Proteins
11
Q
The relation of the individual’s genetic makeup to his or her response to specific drugs
A
Pharmacogenomics
12
Q
Small segments of RNA can interfere with protein synthesis with extreme selectivity has led to investigation of __________ and __________ as therapeutic agents
A
small interfering RNAs (siRNAs), micro-RNAs (miRNAs)
13
Q
Short nucleotide chains that are synthesized to be complementary to natural RNA or DNA, can interfere with the readout of genes and the transcription of RNA.
A
Antisense Oligonucleotides (ANOs)
14
Q
T/F: All substances do not undergo certain circumstances to be toxic.
A
F; can undergo
15
Q
T/F: Chemicals in botanicals (herbs and plant extracts, ”nutraceuticals”) are no different from chemicals in manufactured drugs except for the much greater proportion of impurities in botanicals.
A
T
16
Q
T/F: All dietary supplements and all therapies promoted as health-enhancing, should meet the same standards of efficacy and safety as conventional drugs and medical therapies.
A
T
17
Q
What are the 2 nature of drugs?
A
Pharmacodynamics & Pharmacokinetics
18
Q
Pharmacodynamics or Pharmacokinetics?
Receptor, Receptor Sites
A
Pharmacodynamics
19
Q
Pharmacodynamics or Pharmacokinetics?
Inert Binding Sites
A
Pharmacodynamics
20
Q
Pharmacodynamics or Pharmacokinetics?
Movement of drugs in body
A
Pharmacokinetics?
21
Q
Pharmacodynamics or Pharmacokinetics?
Absorption
A
Pharmacokinetics
22
Q
Pharmacodynamics or Pharmacokinetics?
Distribution
A
Pharmacokinetics
23
Q
Pharmacodynamics or Pharmacokinetics?
Metabolism
A
Pharmacokinetics
24
Q
Pharmacodynamics or Pharmacokinetics?
Elimination
A
Pharmacokinetics
25
Drug Development & Regulation
1. Safety & Efficacy
2. Animal Testing
3. Clinical Trials
4. Patents & Generic Drugs
26
Body of knowledge concerned with action of chemicals on biologic systems, especially by binding to regulatory molecules (receptors) and activating or inhibiting normal body processes
Pharmacology
27
Activator
Agonist
28
Inhibitor
Antagonist
29
Target molecules or regulatory molecules in biological systems
Receptor
30
What do you call the new large molecule drugs that can be receptors themselves and bind endogenous molecules?
Biologicals
31
Drugs that may interact directly with other drugs
Chemical Antagonists
32
Drugs that interact almost exclusively with water molecules
Osmotic Agents
33
Who stated "The dose makes the poison"?
Paracelsus (1493 - 1541)
34
Area of pharmacology concerned with the use of chemicals in the prevention, diagnosis, and treatment of disease, especially in humans.
Medical Pharmacology
35
Area of pharmacology concerned with the undesirable effects of chemicals on biologic systems (e.g., poison)
Toxicology
36
T/F: It is the dose of the drugs that makes the drug lethal or poisonous.
T
37
Finds the exact mechanism of actions of drugs and identifies the receptors
Pharmacogenomics
38
Any substance that brings about change in biologic function through chemical actions (binds to receptors)
Drug
39
Specific molecule in the biologic system that plays a regulatory role
Receptor
40
T/F:
Receptor: No binding site = There is an effect in the body
F; no effect in the body
41
What kind of drugs that are usually easy to eliminate?
Water-soluble drugs
42
No receptor
Inert Substance
43
Chemical components of drugs similar to the human body
1. Inorganic Ions
2. Nonpeptide Organic Molecules
3. Small peptides & proteins
4. Nucleic Acids
5. Lipids
6. Carbohydrates
44
T/F: The body can process what it doesn't t produce.
F; the body can't process
45
Drugs may be synthesized within the body
Hormones
46
Chemicals that are not synthesized in the body
Xenobiotics
47
Drugs that have almost exclusively have harmful
effects.
Poisons
48
Poisons of biologic origin (i.e. synthesized by plants or animals) in contrast to inorganic poisons such as lead and arsenic.
Toxin
49
Physical Nature of Drugs
1. Solid
2. Liquid
3. Gaseous
50
T/F: To interact chemically with its receptor, a drug molecule must have the appropriate size, electrical charge, shape, and atomic composition
T
51
Molecular weight of Lithium
7
52
Molecular weight of Thrombolytic Agents
50,000
53
What MW entails that receptors are small and for selective binding
100 MW
54
What MW is easily distributed but also easily be eliminated?
100 MW
55
MW: Upper limit wherein drugs can traverse within the different barriers of the body
1000 MW
56
MW that may not reach certain areas of the body
1000 MW
57
MW that cannot move within the body and cannot diffuse readily between the different
compartments of the body
>1000 MW
58
MW that is given directly at the site of action and must be administered where they have their effect (usually proteins)
>1000 MW
59
Why does >1000 MW have difficulty in traversing different sites of the body?
They have to fit in / They are prevented by the blood-brain barrier, blood-air barrier, etc.
60
Stereoisomerism / Can exist as enantiomeric pairs
Chirality
61
Affects the potency of the drugs
Chirality
62
A drug that interacts with adrenoceptors, has a **single chiral center and thus two enantiomers**.
Carvedilol
63
Potent beta receptor blocker
(S)(-) isomer
64
Weak beta receptor blocker
(R)(+) isomer
65
An intravenous anesthetic and racemic mixture.
Ketamine
66
Ketamine: (+/-) enantiomer is a more potent anesthetic and less toxic than the (+/–) enantiomer.
+ , -
67
T/F: Enzymes are usually stereoselective, one drug enantiomer is often more susceptible than the other to drug-metabolizing enzymes.
T
68
T/F: At present, only a small percentage of the chiral drugs are clinically marketed as the racemic mixtures the rest are available only as active isomers.
F; At present, only a small percentage of the chiral drugs are clinically marketed as the active isomer the rest are available only as racemic mixtures.
69
Mechanism for Drug Shapes
Lock and Key Mechanism
70
Binds to a specific site and activates the receptor which bring out the effect
Agonist Drugs
71
Binds to a receptor, competes with, and prevents binding by other molecules
Pharmacologic Antagonist
72
Binds at a different site other than the agonist binding site and increases agonist response
Allosteric Activators
73
Binds at a different site other than the agonist binding site and decreases agonist response
Allosteric Inhibitors
74
Binds at the agonist binding site and decreases agonist response
Competitive Inhibitors
75
Several other binding site in receptors and for other chemicals that bind to the receptors
Allosteric Site
76
The presence of the antagonist at the receptor site will block access of agonists to the receptor and prevent the usual agonist effect.
Neutral Antagonism
77
Produce increasing effects with increasing dose (Eventually saturate all receptors and response will plateau)
Agonist alone
78
Agonist + Competitive Inhibitor
Require a higher dose to achieve the similar effect
79
Agonist + Allosteric Activators
Enhances the response/effect produced by agonist with the same dose
80
Agonist + Allosteric Inhibitors
Diminish the response/effect produced by agonist with the same dose
81
Drug Receptor Bonds
Sharing of electrons
Strongest
Electrons are shared in order to stabilize these chemicals
Covalent Bonds
82
Irreversible under biologic conditions / Cannot be easily dislodged
Covalent Bonds
83
Drug Receptor Bonds
More common (+)(-) and weaker
Electrostatic Bonds
84
Can we manipulate Electrostatic Bonds?
Yes
85
Drug Receptor Bonds
Weakest and highly lipid-soluble drugs
Hydrophobic Bonds
86
Interacts with lipids of cell membranes and in the interaction of drugs with the internal walls of receptors
Hydrophobic Bonds
87
Action of the drug in the body
Pharmacodynamics
88
Action of the body on the drug
Pharmacokinetics
89
D + Receptor-Effector → _________ → Effect
Drug-Receptor-Effector
90
D + R → _______ → Effector Molecule → Effect
Drug-Receptor Complex
91
D + R → D-R Complex → ________ → Effector Molecule → Effect
Activation of Coupling Molecule
92
Inhibition of metabolism of endogenous activator → _________ → Increased effect
Increased activator action on an effector molecule
93
Occurs in the absence of the agonist. Some of the receptor pool must exist in Ra form and may produce same physiologic effect as agonist-induced activity
Constitutive / Basal Activity
94
Activates receptor-effector system to the maximum extent (Ra-D pool) {activated form}
Full Agonist
95
Binds to the same receptors and activate them in the same way but do not evoke as great a response
Partial Agonist
96
Binds to a site on the receptor molecule separate from the agonist binding site
Allosteric Modulators
97
Modifies receptor activity without blocking agonist activity
Allosteric Modulators
98
May increase / decrease response to agonist and is also noncompetitive
Allosteric Modulators
99
Drug has a stronger affinity for the Ri pool and reduces constitutive activity
Inverse Agonist
100
Results in effects that are opposite of the effects produced by conventional agonists
Inverse Agonist
101
Binds to a receptor, compete with and prevent binding by other molecules
Antagonist
102
Inactive precursor and must be administered and converted to the active drug by biologic process inside the body
Prodrug
103
Undergoes hepatic metabolism to be come a more active form that will enable them to reach target receptors
Prodrug
104
Movement of molecules through the watery extracellular and intracellular spaces.
Permeation
105
Movement of molecules through the watery extracellular and intracellular spaces.
Aqueous Diffusion
106
Membranes of capillaries with small water-filled pores
Has passive processes
Aqueous Diffusion
107
Governed by Fick's Law
Aqueous Diffusion & Lipid Diffusion
108
What diffusion?
Water-soluble drugs easily diffuse due to the presence of water intracellularly and extracellularly
Aqueous Diffusion
109
Movement of molecules through membranes and other lipid structures
Lipid Diffusion
110
Most important factor for drug permeation
Passive Process
Lipid Diffusion
111
Drugs transported across barriers by mechanisms that carry similar endogenous substances
Transport by Special Carriers
112
Its capacity is limited (limit rate of transport across membranes) and is not governed by Fick's Law
Transport by Special Carriers
113
Transport by Special Carriers
Needs energy
Against a concentration gradients
Activate Transport
114
Transport by Special Carriers
No energy directly required
May utilize another concentration gradient of a substance / use an active receptor
Downhill
Facilitated Diffusion
115
Binding to specialized components (receptors) on cell membranes
Endocytosis
116
Internalization by infolding of the area of the membrane and contents of the vesicle are subsequently released into the cytoplasm
Endocytosis
117
Permits very large or very lipid-insoluble (water soluble) chemicals to enter the cell
Endocytosis
- B12 with intrinsic factor
- Iron with transferrin
118
Reverse process
Expulsion of membrane encapsulated material from the cell
Exocytosis
119
Predicts the movement of molecules across a barrier
Fick's Law of Diffusion
120
Drug absorption is faster in organs with larger surface areas (e.g. small intestine) than from organs with smaller absorbing areas (e.g. stomach)
Fick's Law of Diffusion
121
Fick's Formula
Rate = C1 - C2 x Permeability Coefficient / Thickness x Area
kaya nio n yn
122
HHE: Higher Concentration
C1
123
Lower Concentration
C2
124
Intrinsic property of the drug; measure of the mobility of the drug in medium of the length of the diffusion path.
Permeability Coefficient
125
Length of the diffusion path; Thicker means harder to permeate through.
Thickness
126
Surface area of the membrane
Area
127
Greater concentration difference = ______ ; ______ proportional to the rate
Faster equilibriation ; Directly
128
↑ Permeability Coefficient = ___ Rate
↑
129
Bigger Surface Area = _________ ; ________ proportional to rate
More areas to traverse ; Directly
130
Is a function of the electrostatic charge (degree of ionization, polarity) of the molecule
Aqueous solubility of a drug
131
Water molecules are attracted to _(charged/uncharged)_ drug
Charged
132
Lipid solubility of a molecule is _______ proportional to
its charge
Inversely
133
Lipid Diffusion
Determines the fraction of molecules charged (ionized) versus uncharged (nonionized)
pH of the medium
134
Fraction of molecules in the ionized state can be predicted by means of the H-H equation
Lipid Diffusion
135
Clinically important when it is necessary to estimate or alter the partition of drugs between compartments of different pH
Henderson-Hasselbach Equation
136
Formula for Henderson-Hasselbach
log (protonated) / (unprotonated) = pka - pH
137
T/F: The HHE applies to both acid and basic drugs.
T
138
T/F: In HHE, protonated means associated with a proton (a hydrogen ion / H+)
T
139
Neutral molecule that can form a **cation (+charged)** by combining with a proton (hydrogen ion)
Weak Base
140
Ionized, more polar, more water soluble when they are protonated
Weak Base
141
Neutral molecule that can reversibly dissociate into an **anion (-charged)** a proton (hydrogen ion)
Weak Acid
142
Not ionized, less polar, less water soluble when they are protonated
Weak Acid
143
T/F: Large number of drugs are weak acids with amine containing molecules
F; weak bases
144
T/F: Primary, secondary, and quarternary amines may undergo reversible protonation and vary their lipid solubility with pH, but tertiary amines are always in the poorly-lipid soluble charged form.
F
(1) Primary, secondar, **tertiary**
(2) but **quarternary**
145
Amount absorbed into the systemic circulation amount of drug administered
Bioavailability
146
Important parameter of Bioavailability
Blood Plasma - Looks into the amount of blood present in systemic circulation compared to amount of drug administered
147
- Maximum convenience
- Absorption maybe slower, and less complete
Oral
148
T/F: Some drugs have low bioavailability when given orally
T
149
- Instantaneous and complete absorption
- Bioavailability by definition is 100%
- Potentially more dangerous, high blood levels reached if administration is too rapid
Intravenous (IV) / Parenteral
150
- Absorption is often faster and more complete (higher bioavailability) than oral
- Large volumes (>5 ml into each buttock) if the drug is not irritating
Intramuscular (IM)
151
T/F: Heparin can be given by intramuscular route.
F; It will cause bleeding in the muscle
152
- Slower absorption than IM route
- Heparin can be given by this route, does not cause hematoma
Subcutaneous
153
- Permits absorption direct into the systemic circulation, bypassing hepatic portal circuit and first-pass metabolism
- Slow or fast depending on formulation of the product
Buccal and Sublingual
154
In the pouch between gums and cheeks
Buccal Route
155
Under the tongue
Sublingual Route
156
T/F: Buccal and Sublingual routes offer different features when absorbed.
F; It offers the same features
157
Tend to migrate upward in the rectum where absorption is partially into the portal circulation
Rectal (Suppository)
158
T/F: Larger amounts of unpleasant drugs are better administered rectally
T
159
For respiratory diseases
Inhalation
160
Delivery closest to the target tissue
Inhalation
161
Results into rapid absorption because of the rapid and thin alveolar surface area
Inhalation
162
Drugs that are gases at room temperature (eg, nitrous oxide), or easily volatilized (anesthetics)
Inhalation
163
Application to the skin or mucous membrane of the eye, nose, throat, airway, or vagina for local effect
Topical
164
Rate of absorption varies with the area of application and drug’s formulation and absorption is slower compared to other routes
Topical
165
Application to the skin for systemic effect and rate of absorption occurs very slowly
Transdermal
166
Influences absorption from IM, subcutaneous, and in shock
Blood Flow
167
T/F: High blood flow maintains a high drug depot-to-blood concentration gradient, which maximizes absorption
T
168
Major determinant of the rate of absorption (Fick’s law)
Concentration
169
Subject to first-pass effect
1. Oral
170
First-pass effect is avoided
1. Intramuscular (IM)
2. Subcutaneous
3. Transdermal
171
Partial avoidance of first-pass effect
1. Rectal
172
Significant amount of the agent is metabolized in the gut wall, portal circulation, and liver before it reaches the systemic circulation
First-pass effect
173
Target of cocaine and some tricyclic antidepressants
NET
174
Norepinephrine reuptake from synapse
NET
175
Target of selective serotonin reuptake inhibitors and some tricyclic antidepressants
SERT
176
Serotonin reuptake from synapse
SERT
176
Target of reserpine and tetrabenazine
VMAT
176
Transport of dopamine and norepinephrine into adrenergic vesicles in nerve endings
VMAT
177
Transport of many xenobiotics out of cells
MDR1
178
Leukotriene secretion
MRP1
